Stanford Medicine researchers inhibit protein to restore cartilage in mice
- Researchers at Stanford Medicine have discovered that inhibiting a specific aging-related protein can restore damaged or degenerated cartilage in mice and human tissue samples.
- Osteoarthritis develops as joint cartilage gradually wears away, removing the cushion that prevents bones from grinding together and causing chronic pain, swelling, and mobility loss.
- To target this tissue degradation, the Stanford Medicine team studied 15-PGDH, an enzyme associated with age-related tissue breakdown.
Researchers at Stanford Medicine have discovered that inhibiting a specific aging-related protein can restore damaged or degenerated cartilage in mice and human tissue samples. The finding points toward potential new treatments for osteoarthritis, a degenerative joint condition that currently lacks restorative therapies and often requires joint replacement surgery.
Cartilage Breakdown and Protein Inhibition
Osteoarthritis develops as joint cartilage gradually wears away, removing the cushion that prevents bones from grinding together and causing chronic pain, swelling, and mobility loss. Because cartilage has a minimal capacity to repair itself, standard medical interventions remain limited to pain management or joint replacement surgery.
To target this tissue degradation, the Stanford Medicine team studied 15-PGDH, an enzyme associated with age-related tissue breakdown. Laboratory measurements showed that knee joint cartilage in older mice contained approximately twice as much of this protein as cartilage in younger mice.
When researchers administered a small-molecule drug to inhibit 15-PGDH—using both systemic injections and direct intra-articular knee injections—the cartilage in the older mice thickened until it closely resembled normal joint tissue. The treatment did not require stem cells, operating instead by stimulating existing cartilage cells to resume normal function.
Injury Prevention and Human Tissue Tests
The research team also evaluated the therapy on mice with knee injuries resembling an anterior cruciate ligament (ACL) tear in humans, an injury that frequently leads to post-traumatic osteoarthritis even after surgical repair. Administering the 15-PGDH inhibitor twice weekly for four weeks following the injury significantly reduced the likelihood of osteoarthritis development, while allowing the mice to bear weight and walk closer to normal patterns.
Beyond animal models, investigators tested the approach on human cartilage samples obtained from patients undergoing knee replacement surgery. One week after applying the drug, samples showed reduced levels of the target protein, lower markers of cartilage breakdown, and emerging signals indicating the formation of new surface cartilage.
Clinical Safety Testing and Future Development
Oral formulations of 15-PGDH inhibitors are currently undergoing human clinical trials for age-related muscle weakness, with preliminary safety established in healthy volunteers. Adapting these therapies for cartilage repair will require separate clinical evaluations to confirm safety and efficacy for joint tissues.
If upcoming clinical trials verify the safety and effectiveness of the treatment in humans, investigators aim to develop oral or injectable medications capable of repairing cartilage and decreasing reliance on hip and knee replacement procedures.